RE:RE:RE:RE:Where did the money go?NeilPaert74 wrote: goldn1 wrote:
i am surprised they haven't burned thru more. We all knew they would have to do another raise at some point, hopefully they will hav covid and phase 2 results by the end of the year so it will b @ a much higher price w more institutional investors. If they don't produce anything positive by nov/dec, I think we will see a lot of ppl dumping, including myself as they can't wait until they are out of money until a raise, so I would target jan/feb...
Goldie I agree, I actually think they need to give us some details on what the Covid 19 might give them in grant money $$ at the AGM. I'm assuming 1433, what they have discovered about it, will give them excellent Covid 19 results at the U of M. Dr. Coombs should be able to get grant money for it. At the least TLT won't be spending money there next year. And yes SP should be much higher. Remember though we are still on the Vulture. I'd really like to see TLT make a move to Toronto xchange, at the least!
So yeah by Jan/Feb like you said I'm expecting a very nice belated Christmas present from TLT. :-)
Hi Neil...Dr. Coombs (his specialty is in virology...good for us) has received multiple grants in the past 5 yrs & has recently received a generous grant towards the fight against Covid-19 from CIHR (Canadian Institutes of Health Research). Between this & what TLT provided (my guess 500K to 1M), we should be good to go through next year w/o the need for further funding by TLT as you said. These collaborations TLT is forming (U of M, RP...& which will likely expand) will not only prove our technology/worth, their research will hopefully open the floodgates for more grants/public funding...taking some pressure off TLT's & softening any blow to TLT's coffers in the future when needed. Good luck...
KEVIN COOMBS (MEDICAL MICROBIOLOGY & INFECTIOUS DISEASES/CHILDREN’S HOSPITAL RESEARCH INSTITUTE OF MANITOBA), CIHR AWARDED $790,162
All strategies of rapidly developing tools to mitigate this catastrophic SARS-CoV-2 pandemic are fundamentally dependent on identifying and controlling those proteins that execute the cellular mechanisms critical for the virus to infect and replicate in host cells. Coombs will lead a multi-institutional consortium using a powerful novel tool, called SOMAscan, and next-generation sequencing, to rapidly determine how COVID-19 (SARS-CoV-2 coronavirus) – and a variety of other coronaviruses – affect large numbers of genes and proteins in different human lung cells, the normal target of the COVID-19 virus.